Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.114194 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Hyehyun Jeong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Irinotecan, Oxaliplatin, Oxonic Acid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Servier Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Division of Hematology-Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: yooc@amc.seoul.kr.
Förderung
- Servier Institute
Zitieren
APA
Jeong, H., Kim, B. J., Lee, C. K., Park, I., Zang, D. Y., Choi, H. J., Lee, S. S., Park, D. H., Song, T. J., Oh, D., Moon, S. H., Kim, K. P., Wainberg, Z., Ryoo, B. Y., & Yoo, C. (2024). Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114194
Vancouver
Jeong H, Kim BJ, Lee CK, Park I, Zang DY, Choi HJ, et al. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114194
BibTeX
@article{Jeong2024,
author = {Jeong, Hyehyun and Kim, Bum Jun and Lee, Choong-Kun and Park, Inkeun and Zang, Dae Young and Choi, Hye Jin and Lee, Sang Soo and Park, Do Hyun and Song, Tae Jun and Oh, Dongwook and Moon, Sung-Hoon and Kim, Kyu-Pyo and Wainberg, Zev and Ryoo, Baek-Yeol and Yoo, Changhoon},
title = {Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.114194}
}
EUVIMED